{
  "ticker": "ATX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959902",
  "id": "02959902",
  "pages": 2,
  "price_sensitive": true,
  "date": "20250619",
  "time": "0832",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwrlpwdpmwt3.pdf",
  "summary": "- **Second complete response (CR) recorded** in Amplia's ACCENT trial evaluating narmafotinib + chemotherapy in advanced pancreatic cancer.  \n- **CRs are extremely rare** in advanced pancreatic cancer (historical comparison: 1 CR out of 431 patients in a seminal study).  \n- **Trial details**: Phase 1b/2a open-label study (55 patients enrolled) assessing efficacy (ORR, PFS, OS) and safety.  \n\n*Material impact*: Positive clinical efficacy data may significantly influence valuation due to the rarity of complete responses in this indication. No financial or capital structure updates provided.",
  "usage": {
    "prompt_tokens": 1269,
    "completion_tokens": 130,
    "total_tokens": 1399,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T22:35:27.733881"
}